http://www.biospace.comBioSpace RSS GeneratorThu, 11 Mar 2010 16:44:28 GMT20http://rss.biospace.com/images/BSPLogo.gifhttp://www.BioSpace.com/news.aspx?SectionId=1Copyright (C) 2009http://www.biospace.com/news_story.aspx?StoryID=173575&full=1The Sun News -- AstraZeneca PLC announced a supply partnership with India's Torrent Pharmaceuticals on Thursday, its first such link with a generic drugmaker as it seeks to boost its presence in emerging markets and counter patent losses on blockbuster medicines.Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173553&full=1LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX - News) today announced positive results of a human clinical study that show that its GVAX Leukemia vaccine may be able to reduce or eliminate the last remaining cancer cells in some chronic myeloid leukemia (CML) patients taking the drug Gleevec (imatinib mesylate). All patients enrolled in the trial used Gleevec for...Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173577&full=1MarketWatch -- Basilea Pharmaceutica AG, the Basel drugmaker, said on Thursday that a Johnson & Johnson subsidiary asked the European Committee For Medicinal Products for Human Use to re-examine its rejection of ceftobiprole to treat complicated skin and soft-tissue infections.Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173565&full=1Reuters -- U.S. regulators said on Wednesday they have found no link between oral bisphosphonate osteoporosis medications such as Merck & Co Inc's (MRK.N) Fosamax and certain thigh bone fractures.Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173586&full=1Crains Manchester Business -- More than 200 Manchester-based jobs are under threat at AstraZeneca after the pharmaceutical giant said previously announced plans to outsource some back office functions will affect its office in Chorlton-cum-Hardy.Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173560&full=1FORT LEE, N.J.--(BUSINESS WIRE)--Neurologix, Inc. (OTCBB:NRGX - News), a biotechnology company engaged in the development of innovative therapies for the brain and central nervous system, today announced that Clark A. Johnson, the Vice Chairman of Neurologix (the Company), has been appointed as the Companys President and Chief Executive Officer to replace John E. Mordock, who resigned.</p><p...Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173554&full=1SOUTH SAN FRANCISCO, Calif., March 11 /PRNewswire/ -- Portola Pharmaceuticals, Inc. today announced that Charles Homcy, M.D., president and chief executive officer, will retire from his current position and assume the role of co-chairman of the board of directors, effective May 1, 2010. Dr. Homcy has served as president and CEO since 2003, when he co-founded the company. Chief Operating Officer William...Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173593&full=1<p>NAPA, Calif., March 10 /PRNewswire-FirstCall/ -- Senetek PLC today announced the closing of a Security Purchase Agreement, a Note and a Warrant Purchase Agreement DMRJ Group, LLC on March 4, 2010. DMRJ Group, LLC is a Delaware limited liability company affiliated with Platinum Partners Value Arbitrage Fund L.P., an accredited institutional investor with its investment manager headquartered in New...Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173570&full=1SOUTH SAN FRANCISCO, Calif., March 11, 2010 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN - News) (Stockholm:OXGN - News), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, today announced that it has entered into a definitive agreement with certain institutional investors to sell 6,578,945 shares of its Common Stock and separate series of warrants...Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173580&full=1Alibaba -- There are plans to build the largest global contract bio-pharmaceutical base in Asia in Beijing, with a total investment of about $120 million, Xinhua website reported on March 9.Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173571&full=1ATLANTA, March 11 /PRNewswire/ -- UCB today announced that the antiepileptic drug (AED) Vimpat (lacosamide) (C-V) demonstrated significantly fewer partial-onset seizures versus placebo in adults living with epilepsy, according to a Phase III clinical study published online in Epilepsia.</p><p>This study was one of three that supported the approval of Vimpat by the U.S. Food and Drug Administration...Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173587&full=1Pittsburgh Business Times -- An ambitious plan to build a vaccine factory in the Pittsburgh area is gaining momentum with the announcement Thursday of three new partners in the University of Pittsburgh Medical Center project.Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173578&full=1Bloomberg -- Merck & Co.s Stromectol tablet worked better than lotion at clearing up hard-to-treat head lice, a study found, as the infestations become increasingly resistant to current medicines. Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173684&full=1FORT LEE, N.J., March 10 /PRNewswire/ -- Dainippon Sumitomo Pharma America, Inc. (DSPA), a U.S. subsidiary of Dainippon Sumitomo Pharma Co., Ltd. (DSP), today announced that the U.S. Food and Drug Administration (FDA) recently accepted for review the lurasidone New Drug Application (NDA) for the treatment of patients with acute schizophrenia. The NDA was submitted to FDA on December 30, 2009 and will...Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173686&full=1BRISBANE, Calif., March 9 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) announced that it will hold a webcast of a live conference call today at 5:00 p.m. EST to discuss the outcome of today's Pulmonary-Allergy Drugs Advisory Committee (PADAC). The committee was convened by the U.S. Food and Drug Administration to review and discuss the company's New Drug Application (NDA) for pirfenidone...Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173687&full=1CHICAGO, March 11 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board: ADLS), a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, announced today that the U.S. Food and Drug Administration (FDA) has provided guidance on the clinical program required...Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173592&full=1WORCESTER, Mass., March 11, 2010 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT) (www.generex.com), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, announced today that Health Management Resources, Inc. (HMR) has recently conducted two focus groups in Indianapolis for Generex Oral-lyn. HMR provides educational programs, materials, and services...Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173695&full=1DUBLIN, Ohio--(BUSINESS WIRE)--Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, today announced that it will hold a conference call tomorrow, Friday, March 12, 2010 to discuss the positive outcomes of a recent meeting with the United States Food and Drug Administration (FDA) regarding the clinical trial results of a Phase 3 investigational...Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173588&full=1<p> LEIDEN, The Netherlands and SEATTLE, Washington, March 11, 2010 /PRNewswire/ -- ProFibrix B.V., a leader in the development of innovative products for hemostasis and regenerative medicine, today announced the conclusion of the first Phase II trial testing its unique new hemostat Fibrocaps(TM). Promising preliminary data from the European multicenter, open-label trial show compelling safety and...Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173659&full=1<div id"releaseBody"><p>CALGARY, ALBERTA--(Marketwire - March 10, 2010) - Stem Cell Therapeutics Corp. ("SCT" or the "Company") (TSX VENTURE: <a href"http://www.marketwire.com/mw/stock.jsp?TickerTSXV:SSS">SSS</a>) wishes to announce the acceptance and publication of the paper entitled "The Beta-hCG Erythropoietin in Acute Stroke ( BETAS) Study" by the journal "Stroke", on March 8, 2010...Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173664&full=1<p></p><p>WAYNE, N.J., March 11 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals announced today that an orphan drug designation has been granted by the U.S. Food and Drug Administration (FDA) for ciprofloxacin dry powder inhaler (DPI) for management of pulmonary infection due to Pseudomonas aeruginosa in cystic fibrosis (CF) patients. A similar designation has already been granted by the European...Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173674&full=1<p></p><p></p><p>BRISBANE, Australia, March 11 /PRNewswire/ -- Australian drug development company CBio Limited today announced the achievement of a clinical trial milestone under its option agreement with global pharmaceutical leader Novo Nordisk A/S. The agreement relates to the development of XToll, the potential new-generation drug therapy which could provide safer and more effective treatment...Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173606&full=1RADNOR, Pa.--(BUSINESS WIRE)--PolyMedix, Inc. (OTC BB: PYMX), an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has presented for the first time to the medical community data from its Phase 1B clinical study with its defensin-mimetic antibiotic compound, PMX-30063. The data were presented today at the 8th World...Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173668&full=1<div id"releaseBody"><p>VANCOUVER, BRITISH COLUMBIA--(Marketwire - March 11, 2010) - <a href"http://www.allontherapeutics.com/">Allon Therapeutics Inc.</a> (TSX: <a href"http://www.marketwire.com/mw/stock.jsp?TickerTSX:NPC">NPC</a>) announced today that a Phase 1 clinical trial of its lead neuroprotective drug, <a href"http://www.allontherapeutics.com/development.html">davunetide</a>, which...Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173620&full=1HOUSTON--(BUSINESS WIRE)--Emerging Healthcare Solutions, Inc. (Pink Sheets: EHSI) was pleased on learning the news that Intel, The Mayo Clinic and GE Healthcare have launched a new initiative to study the care and cost benefits of home-based telemedicine for elderly patients with chronic illnesses. Emerging Healthcare Solutions has licensed a cutting-edge mobile telemedicine platform from Telemedicus...Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173647&full=1CARLSBAD, Calif.--(BUSINESS WIRE)--Scientists using advanced genomic analysis technologies from Life Technologies Corporation (NASDAQ: LIFE) have sequenced an individuals genome and identified the specific causative mutation associated with Charcot-Marie-Tooth Disease (CMT), one of the most common inherited neurological disorders currently affecting 1 in 2,500 individuals in the United States.Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173644&full=1STOCKHOLM--(BUSINESS WIRE)--Regulatory News: The Swedish biotech company Karo Bio (Reuters: KARO.ST) today announced the publication of results from a clinical phase II trial evaluating the companys liver selective thyroid hormone receptor agonist eprotirome and its ability to further reduce serum LDL cholesterol levels in statin-treated patients. The results are published in the March 11, 2010 edition...Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173688&full=1London, UK 11 March 2010; Proximagen Neuroscience plc, the leading biotechnology company focused on drug development for diseases of the central nervous system (CNS), today announces headline results from the successful completion of a year-long non-clinical testing programme undertaken by the National Institute of Neurological Disorders and Stroke (NINDS) at the National Institute of Health ...Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173594&full=1NEW YORK, March 11, 2010 (GLOBE NEWSWIRE) -- Laxai Pharma, Ltd. (f/k/a NexGen Biofuels, Ltd.) (OTCBB:NXGNF) today announced that it has completed its first acquisition in the clinical research services space by purchasing all of the assets of OSR Solutions, Inc. ("OSR"), a New Jersey based contract research organization ("CRO"), for $3.6 million consisting of the following: $1.5mm in cash, $0.75mm...Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173601&full=1<p> DUBLIN, March 11, 2010 /PRNewswire/ -- Azur Pharma Limited ("Azur") today announced it has signed a definitive agreement with Elan Pharmaceuticals, Inc. (a subsidiary of Elan Corporation, plc) ("Elan") to acquire the analgesic therapy, PRIALT(R) (ziconotide intrathecal infusion).</p><p> PRIALT is indicated in the United States for the management of severe chronic pain in patients for whom...Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173690&full=1New Milton, Hampshire, UK/Wetzlar, Germany, 11th March 2010 Genetix Ltd, a leading provider of solutions for imaging and image analysis, has been acquired by Leica Microsystems.<p></p>This acquisition brings together Genetix expertise in developing and marketing imaging systems and software for clinical and research applications, with Leica Microsystems microscopes and other life science instrumentation...Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173608&full=1HAMBURG, Germany, March 11, 2010 (GLOBE NEWSWIRE) -- Evotec AG (Frankfurt:EVT) (TecDAX) today announced that it has entered into a collaboration with Active Biotech AB (Stockholm:ACTI) to identify small molecule modulators of a priority biological target, selected by Active Biotech, involved in immune disorders and cancer.Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173621&full=1<p>TORONTO, March 11 /PRNewswire/ - Trillium Therapeutics Inc. (TTI), a biopharmaceutical company developing innovative immune-based biologics, today announced that it has entered into two definitive license agreements with University Health Network (UHN) and The Hospital for Sick Children (SickKids) in Toronto, Ontario, granting Trillium exclusive worldwide rights to commercialize two immunology programs...Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173625&full=1<p></p><p></p><p>ST. LOUIS, March 11 /PRNewswire-FirstCall/ -- Sigma-Aldrich announced today that it has entered into a worldwide licensing agreement with Australia's Commonwealth Scientific and Industrial Research Organization (CSIRO) to manufacture and sell Reversible Addition-Fragmentation chain Transfer (RAFT) agents - organic molecules that can be added to polymerization reactions to precisely...Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173626&full=1ROCHESTER, N.Y. & NEWTON, Pa.--(BUSINESS WIRE)--ACM Global Central Laboratory, the global central lab that continually defines the customer-service standard with its flexible approach, and BioClinicaInc., (NASDAQ: BIOC) a global provider of clinical trial management services, are pleased to announce they are co-sponsoring the upcoming R&D Directions webinar on, How Central Lab and Electronic Data...Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173641&full=1LUND, Sweden & ROCKVILLE, Md.--(BUSINESS WIRE)--BioInvent International AB (STO:BINV) and Human Genome Sciences, Inc. (NASDAQ:HGSI) today announced that they have entered into a collaboration to discover, develop and commercialize therapeutic monoclonal antibodies which specifically target antigens discovered by HGS.Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173648&full=1MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Complete Genomics Inc., a third-generation human genome sequencing company, today announced that the Institute for Systems Biology (ISB) employed Complete Genomics human genome sequencing service to sequence a family quartet to determine the depth of genetic information possible in analyzing a full familys sequence, and to verify the gene responsible for Miller...Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173653&full=1STOCKHOLM--(BUSINESS WIRE)--Regulatory News: Medivir AB (Sweden)(STO:MVIRB) today announced a license agreement with Daewoong Pharmaceutical Co. Ltd., (South Korea) for its hepatitis B virus (HBV) polymerase inhibitor drug, lagociclovir valactate (MIV-210).Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173629&full=1<div id"releaseBody"><p>XI'AN, CHINA--(Marketwire - March 11, 2010) - <b> Skystar </b><b>Bio-Pharmaceutical</b> <b>Company</b> (NASDAQ: <a href"http://www.marketwire.com/mw/stock.jsp?TickerSKBI">SKBI</a>)<b> ("Skystar" or the "Company"),</b> a China-based manufacturer and distributor of veterinary medicines, vaccines, micro-organisms and feed additives, today announced it has retained Grayling...Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173672&full=1<div id"releaseBody"><p>MALVERN, PA--(Marketwire - March 11, 2010) - Auxilium Pharmaceuticals, Inc. (NASDAQ: <a href"http://www.marketwire.com/mw/stock.jsp?TickerAUXL">AUXL</a>),a specialty biopharmaceutical company, today announced the manageddistribution network partners that have been contracted to supportXIAFLEX&#8482; (collagenase clostridium histolyticum), a novel, first-in-class...Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173698&full=1<div id"releaseBody"><p>MALVERN, PA--(Marketwire - March 11, 2010) - Auxilium Pharmaceuticals, Inc. (NASDAQ: <a href"http://www.marketwire.com/mw/stock.jsp?TickerAUXL">AUXL</a>),a specialty biopharmaceutical company, today announced the manageddistribution network partners that have been contracted to supportXIAFLEX&#8482; (collagenase clostridium histolyticum), a novel, first-in-class...Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173651&full=1AUSTIN, Texas--(BUSINESS WIRE)--The Cancer Prevention and Research Institute of Texas (CPRIT) today awarded over $6.8 million to fund twelve new cancer prevention programs through local clinics, health districts, community-based organizations, and academic institutions across the state of Texas. This is the very first round of prevention grants awarded in CPRITs 10-year, $3 billion mission.Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173681&full=1Lewisville, TX - Bio-Synthesis, Inc. announced today that the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH), has awarded the company a 2-year, $590,000, Small Business and Innovation Research (SBIR) Phase 1 grant. The company will use the proceeds to further the development of its proprietary adjuvants or immune agonists that carry in a single...Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173683&full=1NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)--Advaxis, Inc., (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company has developing a long-term, room temperature, storage-stable form of its vaccines. This would replace the current requirement to keep the product frozen at -70o C before use.Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173632&full=1BOTHELL, Wash.--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that the U.S. Patent and Trademark Office has issued a patent related to its antibody-drug conjugate (ADC) technology. U.S. Patent No. 7,659,241 covers cleavable linkers and potent auristatin drug payloads used in certain of Seattle Genetics ADC programs, most notably brentuximab vedotin (SGN-35), as well as many...Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173640&full=1RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc., today announced that the Opposition Division of the European Patent Office (EPO) has issued a written decision confirming its November 18, 2009 revocation of the previously granted claims of Cellectis European Patent No. 1 485 475. As previously reported, after an oral hearing in an Opposition Proceeding initiated by Precision...Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173719&full=1Paris, March 11, 2010 - Hybrigenics, a bio-pharmaceutical company with a focus on research and development of new cancer treatments and specialized in protein interactions, announced today that it has filed a new patent application protecting a crucial step in the synthesis of inecalcitol. The improved chemical process will allow higher yields and lower costs for future industrial batches. Inecalcitol...Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173630&full=1NEWTON, Mass.--(BUSINESS WIRE)--Pro-Pharmaceuticals, Inc. (OTCBB: PRWP) (the Company), today announced that it has closed a $335,000 tranche of a private placement of up to $6.0 million with 10X Fund, L.P., which is purchasing unregistered Series B convertible preferred stock and warrants. This tranche brings the total raised to date from the 10X Fund to approximately $5.1 million.Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173603&full=1<p></p><p>ROCKVILLE, Md., March 10 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. announced today that it will hold its 2010 Annual Meeting of Stockholders on Thursday, June 3, 2010, in Rockville, Maryland. The record date for the Annual Meeting will be April 16, 2010. Only stockholders of record at the close of business on April 16, 2010 may vote at the meeting or any adjournment thereof...Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173642&full=1BROOMFIELD, Colo.--(BUSINESS WIRE)--ARCA biopharma, Inc. (NASDAQ: ABIO), a biopharmaceutical company developing genetically targeted therapies for heart failure and other cardiovascular disease, today announced, as required by NASDAQ Marketplace Rule 5250(b)(2), that the report of the Companys independent registered public accounting firm, included in its previously filed consolidated financial statements...Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173680&full=1<p> HARBIN, China, March 11 /PRNewswire-Asia-FirstCall/ -- Renhuang Pharmaceuticals, Inc. ("Renhuang" or the "Company"), a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and traditional Chinese medicines ("TCM"), announced today that it has recently increased its Shengmai Granules price by 12%. Shengmai Granule is an all-natural traditional Chinese medicine that...Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173675&full=1<p></p><p>PLEASANTON, Calif., March 11 /PRNewswire/ -- Microchip Biotechnologies, a maker of automated microscale biotech laboratory systems, today announced that it has changed its business name to IntegenX. The new name articulates the company's focus on integrating sample preparation and analysis technologies into complete products that address generic problems shared by life science and biotechnology...Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173693&full=1<div id"releaseBody"><p>BOSTON, MA--(Marketwire - March 11, 2010) - <table class"releaseLink"><tr><td class"releaseLink"><b>Highlighted Links</b></td></tr><tr><td><p>&nbsp;</p><a href"http://www2.marketwire.com/mw/mmframe?prid595365&attachid1195109">Tufts CSDD</a></td></tr><tr><td><p>&nbsp;</p><a href"http://www2.marketwire.com/mw/mmframe?prid595365&attachid1195110">Tufts CSDD Impact...Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173707&full=1Join us at your computer on Thursday, March 18, from 4:00-5:00pm (ET in the US) for a free live tutorial on interpreting mouse nomenclature and more.<p></p>As the number and complexity of substrains and mutant mouse strains increases, understanding strain nomenclature is more important than ever. Proper nomenclature communicates the genetic makeup of a mouse strain and helps ensure reliable and reproducible...Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173613&full=1ST. LOUIS--(BUSINESS WIRE)--Covidien (NYSE: COV), a leading global provider of healthcare products, today announced that the U.S. Food and Drug Administration (FDA) and Health Canada have approved the use of the Maria Research Reactor (Maria) in Poland as a site to irradiate highly-enriched uranium targets for Molybdenum 99 (Mo 99) production. Covidien will use the Mo 99 obtained from Maria in the...Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173671&full=1RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Quintiles has expanded its capacity in Africa with the opening of an office in Nairobi, Kenya. A team of locally-based clinical professionals will monitor throughout East Africa, enhancing Quintiles capability to provide clinical research services across the continent.Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173617&full=1<p></p><p>DETROIT, March 11 /PRNewswire-FirstCall/ -- Caraco Pharmaceutical Laboratories, Ltd. has launched oxaliplatin injections. These 50mg and 100mg oxaliplatin injections, which are therapeutically equivalent to Eloxatin(R) from Sanofi-Aventis, received approval from the US Food and Drug Administration (FDA) for Sun Pharma's Abbreviated New Drug Application (ANDA). Oxaliplatin is an anticancer...Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173637&full=1SAN DIEGO--(BUSINESS WIRE)--Illumina, Inc. (NASDAQ:ILMN) today announced that it has sequenced the DNA of American actress Glenn Close, the first publicly named female to have her DNA sequenced to full coverage. The service was completed in Illuminas CLIA certified and CAP accredited laboratory utilizing Illuminas Genome Analyzer technology and following the established process shown at http://www...Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173646&full=1SEATTLE--(BUSINESS WIRE)--The Institute for Systems Biology (ISB) has analyzed the first whole genome sequences of a human family of four. The findings of a project funded through a partnership between ISB and the University of Luxembourg was published online today by Science on its Science Express website. It demonstrates the benefit of sequencing entire families, including lowering error rates, identifying...Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173685&full=1Oxford, UK (9 March 2010) - BD Biosciences, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX), announced today the launch of the BD FACSAria III Cell Sorting System, a next-generation flow cytometer with the ability to run complex multicolor experiments using up to six lasers.<p></p>As the pioneer in flow cytometry, BD Biosciences goal is to expand the range of applications that can...Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173702&full=1Welwyn Garden City - Cresset today announced the release of a new version of its FieldStere bioisostere generator. FieldStere delivers shorter lead optimization cycles to computational and medicinal chemists by enabling them to choose the best syntheses, to fine-tune portions of lead molecules and to scaffold hop to expand into new areas of chemical space.<p></p>FieldStere V2.0 is the first in Cresset...Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173703&full=110 March 2010: Malvern, UK: As sister companies within Spectris plc, Malvern Instruments and Particle Measuring Systems have completed the transfer of sales and support for Particle Measuring Systems products in Sweden, Denmark, Norway and Finland. For many years Malvern subsidiaries in these countries have provided local sales and support for the Particle Measuring Systems portfolio of particle counters...Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173704&full=1Hannover, Germany, March 10, 2010 / b3c newswire / - Entries for the EUROPEAN BIOTECHNICA AWARD 2010 are now being accepted. Upcoming European companies from the biotechnology sector and the life sciences have until 30 April 2010 to submit entries for this prize. Worth 75,000 Euros, the award is presented to new companies for innovative products and services and/or related concepts and business ideas...Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173705&full=1PITTSBURGH and SANTA CLARA, Calif., March 10, 2010 -- Duquesne University and Agilent Technologies Inc. (NYSE: A) today announced that they have established a Center of Excellence (COE) for mass spectrometry at the university.<p></p>The facility enables a wide range of research in the life sciences and environmental analysis, including:<p></p> ? metabolomics and trace lipid analysis, the...Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173699&full=1Cambridge, MA (PRWEB) March 9, 2010At a gathering of life science researchers, bioinformatics developers, and computational biologists, GenomeQuest today announced a comprehensive Application Programming Interface (API) to its fast-growing sequence data management (SDM) platform. With this addition, life science organizations get, for the first time, a complete and cloud-enabled solution for researchers...Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173708&full=1(Shrewsbury and Boston, MA) -- In a significant breakthrough in assisting early-stagedrug development, especially for Central Nervous System (CNS) diseases and conditionssuch as Alzheimers and Parkinsons Disease, Schizophrenia and Post Traumatic StressDisorder (PTSD), Ekam Imaging Inc. is pleased to announce a new service offeringpositioned to transform the way in which new therapies are...Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173717&full=1TINTAGEL, UK (March 9, 2010) Thermo Fisher Scientific, the world leader in serving science, today announced that the Nordlund Centre for Biomedical Structural Biology at Nanyang Technological University in Singapore has purchased its Maybridge Ro3 500 Fragment Library. Nordlund will use this off-the-shelf set of 500 pharmacophorically-rich Maybridge compounds as a globally renowned benchmark fragment...Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173607&full=1BEDFORD, Mass.--(BUSINESS WIRE)--Anika Therapeutics, Inc. (Nasdaq: ANIK) today announced that it plans to issue its fourth-quarter and year-end 2009 financial results after the close of the market on Tuesday, March 16, 2010. The Company plans to hold a conference call the next day (Wednesday, March 17) at 9:00 a.m. ET to discuss its financial results, business highlights and outlook. In addition, the...Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173618&full=1LOS ANGELES--(BUSINESS WIRE)--Abraxis BioScience, Inc. (NASDAQ: ABII), a fully integrated biotechnology company, today reported financial results for the fourth quarter and full year ended December 31, 2009.Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173660&full=1<p>CHICAGO, March 11 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. , a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced its financial results for the fourth quarter and full year ended December 31, 2009.</p><p></p><p>(Logo: http://www.newscom...Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173597&full=1<p>LYNBROOK, N.Y., March 10 /PRNewswire-FirstCall/ -- BioSpecifics Technologies Corp. , a biopharmaceutical company developing first in class collagenase-based products, today announced its financial results for the fourth quarter and full year ended December 31, 2009.</p><p></p><p>"2009 was a great year for XIAFLEX, highlighted by the recent FDA approval for the treatment of Dupuytren's contracture...Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173623&full=1CHARLOTTE, N.C., March 10, 2010 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) today reported financial results for the fourth quarter and full year 2009 and will host a conference call this afternoon at 4:30 PM ET to discuss these results and provide a quarterly update on the Company's development progress.Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173631&full=1MUKILTEO, Wash., March 10, 2010 (GLOBE NEWSWIRE) -- CombiMatrix Corporation (Nasdaq:CBMX) today reported financial results for the three and twelve months ended December 31, 2009. Key highlights for the fourth quarter and through the date of this release include:Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173638&full=1LIVINGSTON, N.J.--(BUSINESS WIRE)--Columbia Laboratories, Inc. (Nasdaq: CBRX) today reported financial results of the three- and twelve-months periods ended December 31, 2009.Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173661&full=1<div id"releaseBody"><p>ZWIJNAARDE, BELGIUM--(Marketwire - March 10, 2010) - Regulated information<p>Strategic highlights<p>Throughout 2009 the global outlook for agricultural business remainedpositive.Heat and drought spells have highlighted the global challenge ofsustainablefood production. The food crisis of 2008 has enhanced political andcorporateinterest in...Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173627&full=1AMITYVILLE, N.Y.--(BUSINESS WIRE)--Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK) today reported results for the quarter ended January 31, 2010.Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173667&full=1<div id"releaseBody"><p>MONTREAL, QUEBEC--(Marketwire - March 11, 2010) - IBEX Technologies Inc. (TSX VENTURE: <a href"http://www.marketwire.com/mw/stock.jsp?TickerTSXV:IBT">IBT</a>), today reported its financial results for the second quarter ended January 31, 2010.<p>HIGHLIGHTS FOR THE QUARTER:<pre>- Quarterly net earnings increased 47% vs. year ago; - EPS double vs. year...Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173595&full=1<p>PISCATAWAY, N.J., March 11 /PRNewswire-FirstCall/ -- Milestone Scientific Inc. , the recognized leader in advanced injection technologies, today announced its full year results for the fiscal year ended December 31, 2009.</p><p></p><p>Financial Highlights When Comparing 12-Months Ended December 31, 2009 with 12-Months Ended December 31, 2008: </p><p></p><p></p><p></p><p>In 2009, Milestone generated...Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173590&full=1HASBROUCK HEIGHTS, N.J., March 11, 2010 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced today its financial results for the year ended December 31, 2009. Nymox reported a net loss of $5,130,074, or $0.17 per share for the year ended December 31, 2009, compared to $4,637,103, or $0.16 per share for same period in 2008. The increase of the net loss for the year is attributable...Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173633&full=1ROCKVILLE, Md., March 10, 2010 (GLOBE NEWSWIRE) -- Nabi Biopharmaceuticals (Nasdaq:NABI) today announced fourth quarter and year-end financial results for the three and twelve month periods ended December 26, 2009.Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173598&full=1<p>TUSTIN, Calif., March 11 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company developing innovative monoclonal antibodies for the treatment of cancer and serious viral infections, today announced financial results for the third quarter of fiscal year (FY) 2010 ended January 31, 2010. The company also provided an update on its clinical programs and...Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173645&full=1MALVERN, Pa.--(BUSINESS WIRE)--Orthovita, Inc. (NASDAQ: VITA), a specialty spine and orthopedic company with a portfolio of orthobiologic and biosurgery products, reported financial results for the quarter and year ended December 31, 2009. Product sales for the quarter ended December 31, 2009 increased 17% to $24.4 million, compared to $20.8 million for the same period in 2008. Product sales for the...Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173691&full=1Lige (Belgium) - March 11, 2010, 7:00 AM CET - OncoMethylome Sciences SA publishes its financial results for the period ended December 31, 2009.<p></p>2009 operational highlights:<p></p> Starting at the end of 2009, OncoMethylome focused its R&D efforts on four core areas: colorectal cancer screening, bladder cancer detection, prostate cancer detection, and pharmacogenomics. In parallel, the...Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173600&full=1PALO ALTO, Calif., March 11, 2010 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) today reported financial results for the fourth quarter and year ended December 31, 2009. The Company's results include the operations of Stem Cell Sciences Plc (SCS) since April 1, 2009.Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173615&full=1LEXINGTON, Mass.--(BUSINESS WIRE)--Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today reported fourth-quarter and full-year 2009 financial results, provided an update on recent progress with its programs, and announced 2010 objectives.Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173624&full=1NEW YORK, March 10, 2010 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (Nasdaq:SIGA), a company specializing in the development of pharmaceutical agents to fight biowarfare pathogens, today announced its financial results for the year ended December 31, 2009.Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173634&full=1VANCOUVER--(BUSINESS WIRE)--Response Biomedical Corporation (TSX: RBM, OTCBB: RPBIF) reported that it recorded total revenues of $9,946,269, an increase of 69% compared to $5,876,337 in 2008. Clinical products revenue for the year ended December 31, 2009 increased 85% to $6,828,651 compared to $3,683,706 in 2008.Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173666&full=1<div id"releaseBody"><p>DUBLIN, IRELAND--(Marketwire - March 11, 2010) - Trinity Biotech plc (NASDAQ: <a href"http://www.marketwire.com/mw/stock.jsp?TickerTRIB">TRIB</a>), aleading developer and manufacturer of diagnostic products for thepoint-of-care and clinical laboratory markets, today announced results forthe quarter ended December 31, 2009 and the disposal of its coagulationbusiness...Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173701&full=1Leuven (BELGIUM) March 9, 2010 TiGenix NV (NYSE EURONEXT: TIG) provides an update on the launch of ChondroCelect and the status of reimbursement applications.<p></p>TiGenix has begun the commercial launch of its lead product, ChondroCelect, for the treatment of cartilage damage in the knee, in the initial target markets which include Germany, Belgium, United Kingdom and the Netherlands. The first...Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173596&full=1SOUTH SAN FRANCISCO, Calif., March 11, 2010 (GLOBE NEWSWIRE) -- Hana Biosciences (OTCBB:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced that Craig W. Carlson has joined its Executive Committee and will assume the title of Chief Financial Officer, effective April 1, 2010. Mr. Carlson will assume responsibility for financial and treasury operations...Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173692&full=1CAMBRIDGE, Mass.--(BUSINESS WIRE)--Agios Pharmaceuticals, the leading biopharmaceutical company focused on discovering and developing novel drugs in the rapidly emerging field of cancer metabolism, today announced the appointment of William Kaelin Jr., M.D., to its scientific advisory board. Dr. Kaelin currently serves as a Professor of Medicine at Harvard Medical School. Dr. Kaelins laboratory focuses...Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173706&full=1Emeryville, CA (PRWEB) March 3, 2010 -- BioSoteria, Inc., a drug safety services and education firm, announced today that Michelle Nolin Flewell, CPLP, the companys Vice President of eLearning and Informatics, was appointed by the Institute for Credentialing Excellence (ICE) to serve on the Certificate Accreditation Program Advisory Council. The Council was recently formed to develop policies and...Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173639&full=1SEATTLE--(BUSINESS WIRE)--ZymoGenetics, Inc. (NASDAQ:ZGEN), today announced that A. Bruce Montgomery, M.D., was named to the companys Board of Directors.Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173656&full=1DENVER--(BUSINESS WIRE)--DaVita Inc. (NYSE: DVA), a leading provider of kidney care services for those diagnosed with chronic kidney disease (CKD), has been recognized as one of FORTUNE Magazines Most Admired Companies in 2010 for the fifth consecutive year. This year, DaVita ranked first among Health Care Medical Facilities overall, and was specifically recognized in the magazines categories of...Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173670&full=1VANCOUVER, British Columbia--(BUSINESS WIRE)--LifeSciences British Columbia today announced the recipients of the 2010 LifeSciences British Columbia Awards. They are:Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173605&full=1CORAL SPRINGS, Fla.--(BUSINESS WIRE)--Nutra Pharma Corp. (OTCBB:NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that it will be exhibiting its over-the-counter (OTC) and prescription pain relievers, Nyloxin OTC and Nyloxin Rx, at the 12th IDGA Battlefield Healthcare Summit in Washington, D.C. The IDGA...Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173643&full=1RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Talecris Biotherapeutics Holdings Corp. (Nasdaq: TLCR) today announced that Lawrence D. Stern, Chairman and Chief Executive Officer of Talecris, will present at the Goldman Sachs Leveraged Finance Healthcare Conference at 8:15 a.m., Wednesday, Mar. 17 at the Goldman Sachs Conference Center in New York.Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173652&full=1FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Imaging Diagnostic Systems, Inc., (OTCBB:IMDS), a pioneer in laser optical breast imaging; exhibited its CT Laser Mammography (CTLM) system at the European College of Radiology, March 4-8, 2010, in Vienna, Austria. ECR 2010 had over 19,000 international delegates, an increase of attendance over the previous years.Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173663&full=1<p></p><p>LITTLE FALLS, N.J., March 11 /PRNewswire-FirstCall/ -- CANTEL MEDICAL CORP. announced today that Andrew A. Krakauer, President & CEO, will be presenting at the Sidoti & Company, LLC Fourteenth Annual New York Emerging Growth Institutional Investor Forum. The formal presentation is scheduled for 2:10 PM ET on Wednesday, March 24, 2010 at the Grand Hyatt New York, with a Q & A session immediately...Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173700&full=1Abilene and Austin, TX -- March 10, 2010 -- Receptor Logic, Inc. announced today that Chief Scientist Jon Weidanz, Ph.D., will be a presenter at the Gordon Research Conference on Antibody Biology and Engineering, Thursday, March 11, 2010, in Ventura, California. Dr. Weidanz will be speaking on the Therapeutic potential of T-cell receptor mimic monoclonal antibodies. His presentation will focus on...Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173718&full=111 March 2010: Malvern, UK: Dr Hanna Jankevics, product technical specialist at Malvern Instruments is presenting the latest in light scattering methodologies for protein and peptide characterisation at The Peptide Conference 2010. The conference takes place at The Wellcome Trust Conference Centre in Cambridge, UK on 30 & 31 March. Dr Jankevics talk, Light scattering for protein and peptide characterisation...Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173602&full=1<p></p><p>CARY, N.C., March 10 /PRNewswire-FirstCall/ -- Cornerstone Therapeutics Inc. , a specialty pharmaceutical company focused on acquiring, developing and commercializing significant products primarily for the respiratory and related markets, today announced that Craig A. Collard, President and Chief Executive Officer, will be presenting a corporate overview at the 30th Annual Cowen & Company...Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173612&full=1SAN DIEGO--(BUSINESS WIRE)--March 11, 2010--Senomyx, Inc. (NASDAQ: SNMX), a leading company focused on using proprietary taste receptor technologies to discover and develop novel flavor ingredients for the food, beverage, and ingredient supply industries, announced today that Kent Snyder, the Companys Chief Executive Officer, will present a corporate overview on Tuesday, March 16, 2010 at 3:30 p...Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173614&full=1EWING, N.J.--(BUSINESS WIRE)--Antares Pharma, Inc. (NYSE Amex: AIS) today announced that Paul K. Wotton, Ph.D., President and Chief Executive Officer, will present at the 22nd Annual Roth OC Growth Stock Conference on Wednesday, March 17, 2010 at 12:30 p.m. ET (Eastern Time).Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173616&full=1PETALUMA, Calif.--(BUSINESS WIRE)--Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) today announced that Hoji Alimi, the companys CEO and founder, will present a corporate overview and business update at the Roth Capital Partners 22nd Annual OC Growth Stock Conference to be held at the Ritz Carlton in Laguna Niguel, California. Mr. Alimis presentation is scheduled on Wednesday, March 17, 2010 at ...Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173619&full=1<p></p><p></p><p>SAN DIEGO, March 10 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the Roth 22nd Annual OC Growth Conference in Laguna Niguel. </p><p></p><p></p><p>If you are unable to attend the webcast and would like further information on this announcement please contact...Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173635&full=1IRVINE, Calif.--(BUSINESS WIRE)--Spectrum Pharmaceuticals, Inc. (NasdaqGM:SPPI), a commercial-stage biotechnology company with a focus in oncology, announced today that an overview of the Companys business strategy will be given at the 22nd Annual ROTH Capital Markets Conference on Monday, March 15, 2010, at 8:00 am Pacific Time. The conference is being held at the Ritz-Carlton Hotel in Laguna Niguel...Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173649&full=1FRAMINGHAM, Mass.--(BUSINESS WIRE)--GTC Biotherapeutics, Inc. (GTC, NASDAQ: GTCB) announced today that Geoffrey Cox, Ph.D., GTCs Chairman and CEO, is scheduled to present on Wednesday, March 17, 2010 at 2:00 p.m. during the ROTH 22nd Annual OC Growth Stock Conference. The conference is being held at the Ritz-Carlton, Laguna Niguel, California from March 15-17, 2010.Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173650&full=1NEWTON, Mass.--(BUSINESS WIRE)--Clinical Data, Inc. (NASDAQ: CLDA), today announced that Drew Fromkin, President and Chief Executive Officer, will be presenting a corporate overview at the Roth 22nd Annual OC Growth Stock Conference. Clinical Data's presentation will take place at 1:30 p.m. PST on Tuesday, March 16, 2010.Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173676&full=1<p> SHENZHEN, China, March 10 /PRNewswire-Asia/ -- Winner Medical Group Inc. , a manufacturer of medical dressings, medical disposables and non-woven PurCotton(R) materials for the medical and consumer products industries, today announced it will present at the 22nd Annual ROTH Capital Partners (ROTH) OC Growth Stock Conference being held March 15 -17, 2010 in Dana Point, California. Presentation...Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173682&full=1<p> CHENGDU, China, March 11 /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical Co., Inc. , a manufacturer and supplier of modernized traditional Chinese medicine ("TCM") based in Chengdu, China, today announced it will present at 22nd Annual ROTH Capital Partners (ROTH) OC Growth Stock Conference being held March 15-17, 2010 in Dana Point, California. Presentation details are noted below.<...Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173694&full=1NEEDHAM, Mass.--(BUSINESS WIRE)--Celldex Therapeutics, Inc. (NASDAQ: CLDX) today announced that Anthony S. Marucci, President and Chief Executive Officer of Celldex, will present on Tuesday, March 16th, at 8:30 a.m. PDT at the 22nd Annual Roth Capital OC Growth Stock Conference taking place at The Ritz-Carlton, Laguna Niguel in Dana Point, CA.Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173696&full=1<div id"releaseBody"><p>MADISON HEIGHTS, MI--(Marketwire - March 11, 2010) - <b> InfuSystem Holdings, Inc. </b>(OTCBB: <a href"http://www.marketwire.com/mw/stock.jsp?TickerINHI">INHI</a>) (OTCBB: <a href"http://www.marketwire.com/mw/stock.jsp?TickerINHIW">INHIW</a>) (OTCBB: <a href"http://www.marketwire.com/mw/stock.jsp?TickerINHIU">INHIU</a>), the leading provider of ambulatory infusion...Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173714&full=1MISSISSAUGA, Canada March 11, 2010 YM BioSciences Inc. (NYSE Amex: YMI, TSX: YM), today announced that that Mr. David Allan, Chairman and CEO, will be presenting at the 22nd Annual ROTH Orange County Growth Stock Conference.<p></p>Where: Ritz-Carlton, Laguna Niguel (Track 8)<br></br> 1 Ritz Carlton Dr.<br></br> Dana Point, CA<p></p>When: March 16th, ...Thu, 11 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173377&full=1Provides Promising Biologic Intended to Treat Multiple Sclerosis and Compounds that Complement Abbott's Existing Diverse Oncology Program</p><p>ABBOTT PARK, Ill. and REDWOOD CITY, Calif., March 9 /PRNewswire-FirstCall/ -- Abbott (NYSE:ABT - News) and Facet Biotech Corporation (Nasdaq:FACT - News) announced today a definitive agreement for Abbott to acquire Facet, enhancing Abbott's early- and mid...Wed, 10 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173410&full=1Dow Jones -- After years of anticipation, a long-acting version of diabetes drug Byetta, sold by Amylin Pharmaceuticals Inc. (AMLN) and Eli Lilly & Co. (LLY), faces a crucial Food and Drug Administration approval decision this week.Wed, 10 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173398&full=1Reuters -- Novartis has taken an exclusive option to develop Transgene's (TRNG.PA) cancer vaccine TG4010, but the deal fell short of investors' hopes, pulling the shares in the French biotechnology company down 12 percent.Wed, 10 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173378&full=1BRISBANE, Calif., March 9 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq:ITMN - News) announced today that the U.S. Food and Drug Administration's (FDA) Pulmonary-Allergy Drugs Advisory Committee (PADAC) voted 9-3 to recommend approval of Esbriet (pirfenidone) for the treatment of patients with idiopathic pulmonary fibrosis (IPF) to reduce decline in lung function. </p><p>IPF is a rare and...Wed, 10 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173195&full=1SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Exelixis, Inc. (Nasdaq:EXEL) today announced a restructuring as a consequence of its continued strategy to focus resources on the development of its key late-stage compounds. As its first priority, the company will aggressively advance XL184, XL147 and XL765, each of which is the subject of a large clinical development program. Additionally, Exelixis retains...Wed, 10 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173403&full=1Reuters -- Cytokinetics Inc (CYTK.O) said its experimental drug for the treatment of a neurodegenerative disease received orphan drug status from U.S. health regulators, sending its shares up 5 percent in premarket trade.Wed, 10 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173393&full=1MORRISTOWN, N.J., March 10 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE:WPI - News), today announced that it has reached a settlement agreement with Takeda Pharmaceutical Company Limited and Takeda Pharmaceuticals North America resolving outstanding patent litigation related to Watson's generic equivalent version of Actos (Pioglitazone Hydrochloride) 15mg, 30mg and 45mg tablets. Under...Wed, 10 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173409&full=1AP -- The chief executive of drugmaker Bristol-Myers Squibb Co., James Cornelius, received a 2009 compensation package valued by The Associated Press at $17 million, down 22 percent from 2008, due to the much lower value of his stock awards.Wed, 10 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173395&full=1PALO ALTO, Calif.--(BUSINESS WIRE)--Affymax, Inc. (Nasdaq: AFFY - News) today announced that it has received a $5 million development milestone payment from Takeda Pharmaceutical Company as part of the companies exclusive global agreement to develop and commercialize Hematide, Affymaxs investigational drug for the treatment of anemia in chronic renal failure patients. The milestone was achieved...Wed, 10 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173413&full=1Neuropharm Group plc (AIM: NPH), a speciality pharmaceutical company focused on neurodevelopmental disorders, today provides an update to shareholders on developments in relation to the proposed sale or merger of the Company.</p><p>Neuropharm has been in discussions with a number of parties since it entered an offer period on 3 November 2009 and announced that it was pursuing a proposed sale or...Wed, 10 Mar 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=173394&full=1PETALUMA, Calif.--(BUSINESS WIRE)--Oculus Innovative Sciences, Inc. (Nasdaq: OCLS - News), a commercial medical technology company that develops, manufactures and markets a family of products based upon the Microcyn Technology platform, today announced that it has received new 510(k) clearance from the U.S. Food and Drug Administration (FDA) for new dermatology indications for Microcyn Skin and Wound...Wed, 10 Mar 2010 12:00:00 AM GMT